secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001193125-25-118882
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Q1 loss $13.9M, revenue $5.9M; appoints new CEO, tebipenem trial interim on track
--------------------------------------------------------------------------------

- Net loss $13.9M ($0.25/share) vs $12.7M loss in Q1 2024; revenue $5.9M down from $9.3M.
- Cash $48.9M plus $23.75M earned GSK milestone payments provides runway into Q2 2026.
- Esther Rajavelu appointed President & CEO effective May 2, 2025; continues as CFO & Treasurer.
- Phase 3 PIVOT-PO interim analysis for tebipenem HBr expected Q2 2025; SPR720 program suspended after missing endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/0001193125-25-118882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/d918635d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-118882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer